Search
Butamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawn[A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics. … Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate.
Apalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant … Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295].
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. … [A6921] Ofatumumab was first approved by the FDA in 2009.
Tofersen
go.drugbank.com/drugs/DB14782ApprovedInvestigational[A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation. … [L46133] In June of 2024, it was additionally approved by the EMA for the same indication.
Synonyms: -(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R, DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SPIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Beeswax
go.drugbank.com/drugs/DB11600ApprovedBeeswax is used as a stiffening agent in ointments and creams, and enables water to be incorporated to produce water-in-oil emulsions.
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalPPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not … As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically
alpha-Linolenic acid
go.drugbank.com/drugs/DB00132ApprovedInvestigationalNutraceuticalWithdrawnIt is a component of many common vegetable oils and is important to human nutrition.
Mixtures: UltimateCare ONE NFDaclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnRegardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by … and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) [L1744].
Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114] … , as well as to regions containing high levels of melanin, neuromelanin, and iron.